- About Us
- Phase I
- Phase II
- Data Services
- Core Laboratories
- Media Center
- Contact Us
Lannett, a Philadelphia, Pa.-based developer and marketer of generic pharmaceutical products, has signed a definitive agreement to acquire privately held, New York-based Silarx Pharmaceuticals and a related real estate entity, a manufacturer and marketer of liquid generic pharmaceutical products. The transaction is expected to close in early June, subject to customary closing conditions. Strategic benefits of the acquisition include an FDA-approved manufacturing facility, research R&D experience and added diversity to Lannett’s portfolio of existing and pipeline products.
Forum Pharmaceuticals, a biopharmaceutical company focused on the development and delivery of innovative medicines to treat serious brain diseases, has relocated its corporate headquarters to a 112,500-square-foot, state-of-the-art facility located in Waltham, Mass. The move consolidates Forum’s operations into a single centralized location that houses corporate offices, clinical development and research laboratories. Previously, Forum conducted business from two locations in Watertown, Mass. and Brighton, Mass. The company also maintains a small European office in the Netherlands.
Janssen Supply Chain has expanded its partnership with the Rutgers University School of Engineering by providing over $6 million to expand ongoing research efforts supporting the company’s introduction of continuous manufacturing techniques for pharmaceuticals.
Clock and Narcolepsy Genetic Variants and the Effects of Stalevo® (Levodopa/Carbidopa/Entacapone) on Sleep Disorders in Parkinson's Disease
Status: Active, not recruiting, Condition Summary: Parkinson Disease; Sleep Disorders
Status: Completed, Condition Summary: Chronic Kidney Disease (CKD)
FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood
The U.S. Food and Drug Administration (FDA) is warning that the type 2 diabetes medicines canagliflozin, dapagliflozin, and empagliflozin may lead to ketoacidosis, a serious condition where the body produces high levels of blood acids called ketones that may require hospitalization.
Status: Completed, Condition Summary: Alzheimer's Disease
Status: Completed, Condition Summary: Alzheimer Disease
CluePoints, a provider of Centralized Statistical Monitoring (CSM) solutions for clinical trials, has announced that the U.S. Patent and Trademark Office has granted a Notice of Allowance for Application No. 13/452,338, a patent which covers the company's SMART engine. The patent provides broad coverage for CluePoints' proprietary methodology that supports a risk-based approach to data monitoring in clinical trials.
The Alliance for Clinical Research Excellence and Safety (ACRES) has added Dr. Judith Beach, senior vice president and senior associate general counsel for regulatory affairs at Quintiles, to its board of directors. Beach brings her wide-ranging experience in legal and regulatory counsel on international and domestic regulatory issues in the pharmaceutical, medical device and biotechnology industries, as well as her chief privacy officer responsibilities, to ACRES mission of building a global system for accountable clinical research.
Ireland-based Endo International has agreed to acquire privately held, Woodcliff Lake, N.J.-based Par Pharmaceutical from TPG for $8.05 billion, including assumption of Par debt. The transaction has been unanimously approved by the boards of directors of both Endo and Par and is supported by the management teams of both companies. There are no further shareholder approvals required.
Redx Pharma has launched its third subsidiary, Redx Immunology, which will focus on developing new therapies for disorders of the immune system.
Human Longevity (HLI), a San Diego-based, privately held company building a comprehensive database of human genotypes and phenotypes, and the Cleveland Clinic, a nonprofit multispecialty academic medical center, have inked a broad collaboration agreement to first sequence and analyze blood samples from Cleveland Clinic's GeneBank study of de-identified patients.
Circassia Pharmaceuticals has made an all cash offer to acquire Aerocrine, a Swedish company focused on the development and commercialization of medical diagnostic products for use in the diagnosis and management of patients with asthma, for up to $216.4 million.
The California Institute of Technology (Caltech) has partnered with OMT Therapeutics, a private, California-based biotech company, to use OMT Therapeutics’ fully human nanobody platform, UniRat, for the generation of nanobodies against HIV-1.
Ablynx, a biopharma company headquartered in Belguim, has entered into an exclusive research collaboration with Genzyme, a Sanofi company, to investigate nanobodies against a multiple sclerosis (MS) target specifically aligning with Genzyme's early-stage MS research programs involving neuroprotection and CNS repair.
Technology has amazing potential in clinical research, although often it is met with reluctance, resulting in slower adoption.
Data updated through September 16, 2013.
The list has been updated through April 2015.
DAC Patient Recruitment Services, a patient recruitment and retention for global clinical trials company, earned a Gold Award in the 2015 Hermes Creative Awards. Hermes awards are presented to those entries judged to exceed the high standards of the industry norm.